PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsHydroxyamphetamine
Hydroxyamphetamine
Paredrine, Paremyd (hydroxyamphetamine) is a small molecule pharmaceutical. Hydroxyamphetamine was first approved as Paredrine on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydroxyamphetamine hydrobromide
+
Tropicamide
Tradename
Company
Number
Date
Products
PAREMYDEpic PharmaN-019261 DISCN1992-01-30
1 products, RLD
Hide discontinued
Hydroxyamphetamine hydrobromide
Tradename
Company
Number
Date
Products
PAREDRINEPharmicsN-000004 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
paremydNew Drug Application2022-09-14
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
427 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vitamin d deficiencyD014808EFO_0003762E55643155379
Ocular hypertensionD009798EFO_1001069H40.01965222
GlaucomaD005901EFO_0000516H401954220
Open-angle glaucomaD005902EFO_0004190H40.1—754319
HypertensionD006973EFO_0000537I101942318
Chronic renal insufficiencyD051436—N1821—1812
Healthy volunteers/patients———2121612
Covid-19D000086382—U07.12321611
ObesityD009765EFO_0001073E66.9———189
Orthostatic hypotensionD007024—I95.1—13149
Show 49 more
Indications Phases 3
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney diseasesD007674EFO_0003086N083———69
Insulin resistanceD007333EFO_0002614E88.8191———34
Frontotemporal dementiaD057180—G31.01———12
Malabsorption syndromesD008286EFO_0009554K901————1
GastroenteritisD005759EFO_1001463K52.91————1
Crohn diseaseD003424EFO_0000384K501————1
Mucinous adenocarcinomaD002288——1————1
Rectal neoplasmsD012004——1————1
CystadenocarcinomaD003536——1————1
AphasiaD001037—R47.011————1
Show 12 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfertilityD007246EFO_0000545—————55
PeriodontitisD010518EFO_0000649K05.3————55
Periodontal diseasesD010510—K05.6————44
Premature birthD047928EFO_0003917O60————44
Inflammatory bowel diseasesD015212EFO_0003767—————44
Low back painD017116—M54.5————44
Back painD001416—M54————44
AnemiaD000740EFO_0004272D64.9————33
Mental disordersD001523EFO_0000677F91.9————33
Joint diseasesD007592—M12.9————33
Show 198 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHydroxyamphetamine
INNhydroxyamfetamine
Description
4-(2-aminopropyl)phenol is a member of amphetamines.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(N)Cc1ccc(O)cc1
Identifiers
PDB—
CAS-ID103-86-6
RxCUI—
ChEMBL IDCHEMBL1546
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDFQR280JW2N (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,011 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
31 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use